Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Zscaler Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Zscaler Inc trades at $214.06 (market cap $36.00B). The key difference: Zscaler Inc is far larger — about 36.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Zscaler Inc for 41 Days on average.
| MRVI | ZS | |
|---|---|---|
Market Cap | $977.37M | $36.00B |
Volume | 2,742,564 | 2,901,773 |
Sector | Health | Technology |
52-Week High | $9.00 | $336.27 |
52-Week Low | $2.83 | $118.05 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $1.08B | $34.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Zscaler (ZS) trades at $228.66, up 1.28% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -1.88% net margin. Recent earnings beats and 79.6% analyst buy ratings support optimism, while the stock faces headwinds from executive turnover and negative cash flow projections for 2026.
ZS presents a growth-focused opportunity in cybersecurity with AI-driven bookings up 50% sequentially, but investors must weigh high valuations (P/S 10.79) against persistent profitability challenges and near-term execution risks following the chief revenue officer departure. The consensus price target of $222.83 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
